10 Best Performing Growth Stocks in 2025

6. Zai Lab Limited (NASDAQ:ZLAB)

YTD-Performance: 39.82%

Number of Hedge Fund Holders: 26

Zai Lab Limited (NASDAQ:ZLAB) is a biopharmaceutical company that discovers, develops, and sells medicines. The company aims to address unmet medical needs in areas like cancer, autoimmune diseases, infectious diseases, and central nervous system disorders. It has a range of drug candidates, including ZEJULA, OPTUNE, QINLOCK, NUZYRA, and VYVGART.

On March 3, Analyst Jonathan Chang from Leerink Partners reiterated a Buy rating on the stock with a price target of $74. The rating was based on the company’s strong financial performance and advancements in its product pipeline. Chang noted that the company experienced a significant year-over-year revenue increase, which was primarily due to the successful launch of Vyvgart and increased sales of Zejula and Nuzyra. This demonstrates Zai Lab Limited’s (NASDAQ:ZLAB) ability to effectively commercialize its products and capture market share. The analyst also highlighted that the company is strategically focused on advancing its pipeline, particularly ZL-1310, which he thinks is noteworthy. The company is preparing for multiple data updates and a pivotal study initiation for ZL-1310, which could potentially lead to accelerated FDA approval. It is one of the best-performing growth stocks in 2025.